Table 2.

Effects of placebo or simvastatin on lipids, endothelium, and endocrine parameters in hypercholesterolemic patients

			Simvastatin
	Placebo		10 mg		20 mg		40 mg		80 mg
	Baseline	Treatment	Baseline	Treatment	Baseline	Treatment	Baseline	Treatment	Baseline	Treatment	ANOVA
n	32		30		32		31		31
Age (years)	59 ± 2		57 ± 2		58 ± 2		60 ± 2		59 ± 2		0.676
Sex (male/female)	15/17		14/16		15/17		14/17		15/16
BMI (kg/m2)	25.7 ± 0.6	25.5 ± 0.6	25.9 ± 0.7	26.0 ± 0.7	27.0 ± 0.5	26.8 ± 0.5	26.8 ± 0.6	26.8 ± 0.6	26.4 ± 0.5	26.3 ± 0.5	0.444
Lipids (mg/dl)
Total cholesterol	267 ± 6	247 ± 6‡	246 ± 3	179 ± 5‡∥	256 ± 7	191 ± 6‡∥	264 ± 6	166 ± 5‡∥	253 ± 6	155 ± 6‡∥	<0.001
Triglycerides	146 ± 15	159 ± 18	131 ± 12	124 ± 8	147 ± 18	124 ± 16*	149 ± 16	135 ± 13	151 ± 11	119 ± 7†	0.149
LDL cholesterol	179 ± 6	162 ± 6†	162 ± 3	99 ± 4‡∥	174 ± 7	109 ± 6‡∥	181 ± 7	88 ± 5‡∥	170 ± 5	79 ± 5‡∥	<0.001
ApoB	134 ± 4	129 ± 4	125 ± 3	93 ± 3‡∥	131 ± 3	91 ± 3‡∥	139 ± 4	89 ± 4‡∥	129 ± 5	74 ± 4‡∥	<0.001
HDL cholesterol	57 ± 2	54 ± 2	54 ± 1	52 ± 2	52 ± 2	49 ± 2	54 ± 2	48 ± 2†	53 ± 2	53 ± 3	0.316
ApoA-I	161 ± 3	164 ± 4	160 ± 4	170 ± 4	160 ± 4	161 ± 4	164 ± 4	168 ± 5	161 ± 5	163 ± 4	0.514
Vasomotor
FMD dilation(%)	4.69 ± 0.22	4.91 ± 0.16	4.82 ± 0.26	7.70 ± 0.29∥	5.00 ± 0.21	6.78 ± 0.16∥	4.78 ± 0.26	6.74 ± 0.32‡∥	4.92 ± 0.30	7.53 ± 0.41‡∥	<0.001
NTG dilation(%)	14.14 ± 0.65	13.98 ± 0.54	14.60 ± 0.68	14.66 ± 0.63	14.22 ± 0.51	14.32 ± 0.61	14.04 ± 0.60	14.42 ± 0.77	14.08 ± 0.70	14.16 ± 0.69	0.976
Inflammation
hsCRP (mg/l)	0.95 (0.46–2.10)	0.90 (0.35–1.95)	0.64 (0.27–2.91)	0.43 (0.27–1.01)	1.05 (0.40–2.35)	0.90 (0.50–1.95)	0.73 (0.44–1.39)	0.59 (0.38–1.44)	1.52 (0.89–4.82)	0.89 (0.64–3.05)	0.363
Insulin resistance
ADP (μg/ml)	6.6 ± 1.0	6.6 ± 0.9	6.4 ± 1.0	5.9 ± 0.9*∥	6.0 ± 1.0	5.3 ± 1.0*∥	6.2 ± 0.8	5.7 ± 0.7*	6.4 ± 0.8	5.7 ± 0.7*∥	0.011
Insulin (μU/ml)	3.31 ± 0.45	3.04 ± 0.33	3.02 ± 0.49	3.59 ± 0.43	2.95 ± 0.44	5.01 ± 0.70†	2.98 ± 0.31	4.27 ± 0.48†	3.14 ± 0.31	3.56 ± 0.32	0.006
Glucose (mg/dl)	95 ± 4	89 ± 3	89 ± 9	87 ± 8	86 ± 3	84 ± 3	91 ± 4	91 ± 5	91 ± 2	98 ± 4*	0.501
QUICKI¶	0.43 ± 0.01	0.44 ± 0.01	0.46 ± 0.02	0.43 ± 0.01*∥	0.46 ± 0.02	0.41 ± 0.01†∥	0.44 ± 0.02	0.41 ± 0.01*	0.44 ± 0.02	0.41 ± 0.01*∥	0.034

Data are expressed as means ± SEM or median (range). There were no significant differences among baseline values.

^*P < 0.05

^†P < 0.01

^‡P < 0.001 for comparison with each baseline value

^∥P < 0.05 for comparison with the value after therapy with placebo.

^¶QUICKI = 1/[log (insulin) + log (glucose)] (20). ADP, adiponectin; Apo, apolipoprotein; hsCRP, high-sensitivity CRP; NTG, nitroglycerin.